Acute Thrombotic Events in Association With Coronavirus Disease of 2019 Immunization as Initial Presentation of Congenital Factor VII Deficiency.
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
received:
09
02
2023
accepted:
28
04
2023
medline:
28
7
2023
pubmed:
26
7
2023
entrez:
26
7
2023
Statut:
ppublish
Résumé
Coagulation factor VII (FVII) deficiency is a congenital disorder with heterogeneous clinical phenotypes ranging from asymptomatic to life-threatening bleeding and/or thrombotic events. We present the case of an adolescent male who developed acute deep and superficial venous thromboses of the upper extremities in the setting of multiple peripheral venous line insertions and shortly after receiving his second coronavirus disease of 2019 immunization dose. A hemostatic work-up revealed low FVII activity levels associated with 4 different FVII genetic variants. We highlight the need to better understand the pathophysiologic mechanisms behind FVII deficiency-associated prothrombotic risk and the role that specific FVII genetic variants may play in the clinical presentation of these patients.
Identifiants
pubmed: 37494615
doi: 10.1097/MPH.0000000000002705
pii: 00043426-202308000-00034
doi:
Substances chimiques
Factor VII
9001-25-6
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e781-e783Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Marty S, Barro C, Chatelain B, et al. The paradoxical association between inherited factor VII deficiency and venous thrombosis. Haemophilia. 2008;14:564–570.
Mariani G, Herrmann FH, Schulman S, et al. Thrombosis in inherited factor VII deficiency. J Thromb Haemost. 2003;1:2153–2158.
Elkhateb IT, Mousa A, Mohye Eldeen R, et al. Accidentally discovered high INR in pregnancy unmasks an inherited factor VII (FVII) deficiency that is paradoxically associated with thrombotic tendency. BMJ Case Rep. 2021;14:e237781.
Bernardi F, Mariani G. Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis. Haematologica. 2021;106:351–362.
Girolami A, de Marinis GB, Vettore S, et al. Congenital FVII deficiency and pulmonary embolism: a critical appraisal of all reported cases. Clin Appl Thromb Hemost. 2013;19:55–59.
Ramdass SK, Loh KP, Howard LM. Thrombosis in a bleeding disorder: case of thromboembolism in factor VII deficiency. Clin Case Rep. 2017;5:277–279.
Conway EM, Mackman N, Warren RQ, et al. Understanding COVID-19-associated coagulopathy. Nat Rev Immunol. 2022;22:639–649.
Goshua G, Pine AB, Meizlish ML, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020;7:e575–e582.
Iba T, Warkentin TE, Thachil J, et al. Proposal of the definition for COVID-19-associated coagulopathy. J Clin Med. 2021;10:191.
Atyabi SMH, Rommasi F, Ramezani MH, et al. Relationship between blood clots and COVID-19 vaccines: a literature review. Open Life Sci. 2022;17:401–415.
Tobaiqy M, MacLure K, Elkout H, et al. Thrombotic adverse events reported for Moderna, Pfizer and Oxford- AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance Database. Vaccines (Basel). 2021;9:1326.
Shahbazi S, Mahdian R. Factor VII gene defects: review of functional studies and their clinical implications. Iran Biomed J. 2019;23:165–174.
Napolitano M, Siragusa S, Mariani G. Factor VII Deficiency: clinical phenotype, genotype and therapy. J Clin Med. 2017;6:38.
Girolami A, Bertozzi I, Rigoni I, et al. Congenital FVII deficiency and thrombotic events after replacement therapy. J Thromb Thrombolysis. 2011;32:362–367.
Girolami A, Berti de Marinis G, Bonamigo E, et al. Worldwide diffusion of FVII Arg304Gln coagulation defect (FVII Padua). Eur J Haematol. 2011;86:135–139.
Mingot-Castellano ME, Butta N, Canaro M, et al. COVID-19 vaccines and autoimmune hematologic disorders. Vaccines (Basel). 2022;10:961.
Chui CSL, Fan M, Wan EYF, et al. Thromboembolic events and hemorrhagic stroke after mRNA (BNT162b2) and inactivated (CoronaVac) covid-19 vaccination: a self-controlled case series study. EClinicalMedicine. 2022;50:101504.
Corrales-Medina FF, Raffini L, Recht M, et al. Direct oral anticoagulants in pediatric venous thromboembolism: experience in specialized pediatric hemostasis centers in the United States. Res Pract Thromb Haemost. 2023;7:100001.
Davila J, Cheng D, Raffini L, et al. Characterizing the use of anticoagulants in children using the American Thrombosis and Hemostasis Network Dataset (ATHNdataset). Thromb Res. 2021;197:84–87.
Young G, Lensing AWA, Monagle P, et al. Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation. J Thromb Haemost. 2020;18:1672–1685.
Investigators TE. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–2510.
Benlakhal F, Mura T, Schved JF, et al. A retrospective analysis of 157 surgical procedures performed without replacement therapy in 83 unrelated factor VII-deficient patients. J Thromb Haemost. 2011;9:1149–1156.